Search Results - covid-19

7 Results

Sort By:

Tempol as a Therapeutic to Treat Covid-19 Via Inhibition of Viral Replication

Abstract: Despite several partially effective prophylactic vaccines for SARS-CoV-2 exist, patients worldwide still succumb to COVID-19. New therapeutics to treat this disease are still needed. Upon host invasion, a critical step in the pathogenesis of COVID-19 is intracellular replication of SARS-CoV-2 before viral particles invade nearby healthy cells....

Published: 4/8/2024 | Inventor(s): Tracey Rouault, William Linehan, Nunziata Maio

Keywords(s): ANTIVIRAL, COVID-19, RdRP Inhibitor, RNA-dependent RNA Polymerase inhibitor, Rouault, SARS-CoV-2, Tempol

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology

RNASEH-Assisted Detection Assay for RNA

Abstract: Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 – have profoundly impacted global human health. Early identification of infected and/or infectious...

Published: 8/14/2024 | Inventor(s): G Esta Sterneck, Dipak Poria

Keywords(s): COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration

Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method

Abstract: DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab...

Published: 4/8/2024 | Inventor(s): Bin Guan, Robert Hufnagel

Keywords(s): Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus

Category(s): TherapeuticArea > Oncology, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Therapeutics Against Pathogenic Coronaviruses

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available...

Published: 4/8/2024 | Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty

Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...

Published: 7/29/2024 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)

The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...

Published: 7/25/2024 | Inventor(s): Qi Zhang, Wei Zheng, Catherine Chen, Yihong Ye

Keywords(s): COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics